Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Monograph from the Acute Leukemia Forum 1999 on Advances and Controversies in the Therapy of Acute Myelogenous Leukemia
  • Published:

Treatment of acute myelogenous leukemia in older adults

Leukemia volume 14, pages 480–487 (2000)Cite this article

Acute myelogenous leukemia (AML) in older adults is the most frequent form of AML and has a dismal long-term prognosis. The median age of patients with AML is around 64 years, and the incidence increases with age and rises from approximately 5 per 100000 at age 60 to 17 per 100000 at age 80.1

Older adults generally have more unfavorable prognostic factors at presentation and their treatment is made more difficult by their inability to withstand the intensity of chemotherapy. Further, the type of post-remission therapy that they receive is generally considered sub-optimal even for the less poor prognostic groups seen in younger adults. In essence, that is the crux of the problem; a biologically unfavorable disease that gets treated sub-optimally (Table 1).

Table 1  AML in older adults – clinical and biologic features that distinguish this from the more characteristic AML seen in younger adults
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Rowe JM . Acute Leukemia Forum’98: advances and controversies in the biology and treatment of acute myelogenous leukemia and myelodysplasia: introduction Leukemia 1998 12: (Suppl. 1) 1

    Article  Google Scholar 

  2. Löwenberg B, Sucieu S, Archimbaud E, Haak H, Stryckmans P, deCataldo R, Detter AW, Berneman ZN, Thycca A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R . Mitoxantrone versus daunorubicin in induction and consolidation therapy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Organization for the Research and Treatment of Cancer and the Dutch–Belgium Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9 J Clin Oncol 1998 16: 872–880

    Article  Google Scholar 

  3. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Berghe H, Bloomfield CD, de la Chappelle A, DeWald G, Garson OM . Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia Cancer Genet Cytogenet 1994 73: 127–134

    Article  Google Scholar 

  4. Stone RM . Therapy of older adults with AML: CALGB studies. In: Hiddemann W, Büchner T, Wörmann B et al (eds). Acute Leukemias VIII: Prognostic Factors and Treatment Strategies Springer-Verlag: Berlin, Heidelberg 1999 (in press)

  5. Rowley JD, Alimena G, Garson OM, Hageneijer A, Mitelman F, Prigogina EL . A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patients age and karyotype Blood 1982 59: 1013–1032

    CAS  PubMed  Google Scholar 

  6. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DP, Schiffer CA, Arthur DC, Mayer RJ . Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetics subtype Cancer Res 1998 58: 4173–4179

    CAS  PubMed  Google Scholar 

  7. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH . Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission New Engl J Med 1998 339: 1649–1656

    Article  CAS  Google Scholar 

  8. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 1997 89: 3323–3329

    CAS  PubMed  Google Scholar 

  9. Larson RA . Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome Leukemia 1996 10: (Suppl. 1) 23–25

    Google Scholar 

  10. Goasguen JE, Matsuo T, Cox C, Bennett JM . Evaluation of thedysmyelopoiesis in 337 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival Leukemia 1992 6: 520–525

    CAS  PubMed  Google Scholar 

  11. Willman CL . Molecular genetic features of myelodysplastic syndromes (MDS) Leukemia 1998 12: (Suppl. 1) 2–6

    Google Scholar 

  12. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Tempin F, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B . Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 1991 77: 1666–1674

    CAS  PubMed  Google Scholar 

  13. Volger WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC . A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group J Clin Oncol 1992 10: 1103–1111

    Article  Google Scholar 

  14. Wiernik PH, Banks PLC, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch TS, Enck RE, Weitberg AB . Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 1992 79: 313–319

    CAS  PubMed  Google Scholar 

  15. Berman E, Arlin ZA, Gaynar J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N, Clarkson B . Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol Leukemia 1989 3: 115–121

    CAS  PubMed  Google Scholar 

  16. Arlin Z, Zase DC Jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K . Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group Leukemia 1990 4: 177–183

    CAS  PubMed  Google Scholar 

  17. Hansen OP, Pedersen-Bjergaard J, Ellegaard G, Brincker H, Doesen AM, Christen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, Killmann SD, Jensen MK, Karle H, Laursen B, Nielsen JB, Nissen NI, Thorling K . Aclarubicin plus cytosine arabinoside vs daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish National Phase III Trial for the Danish Society of Hematology Study Group on AML Leukemia 1991 5: 510–516

    CAS  PubMed  Google Scholar 

  18. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, Falconi E, Geraci E, Ladogana S, Latagliata R, Malleo C, Nobile F, Petti N, Rotoli B, Specchia G, Tabilio A, Resegotti L . A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia: a multicentric study from the Italian Co-operative Group GIMEMA Eur J Cancer 1991 27: 750–755

    Article  CAS  Google Scholar 

  19. AML Collaborative Group . A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukemia Br J Haematol 1998 103: 100–109

    Article  Google Scholar 

  20. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary A, Tallman MS, Wiernik PH . A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993) Blood 1998 22: (Suppl. 1) 1284a

    Google Scholar 

  21. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH . Randomized placebo-controlled phase III study of granulocyte–macrophage colony stimulating factor in adult patients (>55–70 years) with acute myelogenous leukemia: a Study of the Eastern Cooperative Oncology Group (E1490) Blood 1995 86: 457–462

    CAS  PubMed  Google Scholar 

  22. Hewlett J, Kopecky KJ, Head D, Eyre HJ, Elias L, Kingsbury L, Balcerzak SP, Dabich L, Hynes H, Bickers JN . A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): A Southwest Oncology Group study Leukemia 1995 9: 562–569

    CAS  PubMed  Google Scholar 

  23. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S . On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group J Clin Oncol 1989 7: 1268–1274

    Article  Google Scholar 

  24. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, Desablens B, Henry-Amar M, Degos L . Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly J Clin Oncol 1990 8: 272–279

    Article  CAS  Google Scholar 

  25. Cheson BD, Jasper DM, Simon R, Friedman MA . A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes J Clin Oncol 1986 40: 1857–1864

    Article  Google Scholar 

  26. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K . Randomised comparison of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties Lancet 1998 351: 700–708

    Article  CAS  Google Scholar 

  27. Mayer RJ, Davis RB, Schiffer CH, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III . Intensive postremission chemotherapy in adults with acute myeloid leukemia New Engl J Med 1994 31: 896–903

    Article  Google Scholar 

  28. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O'Connell MJ . Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia J Clin Oncol 1988 6: 583–587

    Article  CAS  Google Scholar 

  29. Büchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kause R, Zeile G . Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group J Clin Oncol 1985 3: 1583–1589

    Article  Google Scholar 

  30. Nicolaou KC, Pitsinos EN, Theodorakis EA, Saimoto H, Wrasidlo W . Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis Chem Biol 1994 1: 57–66

    Article  CAS  Google Scholar 

  31. Matthews DC . Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome Leukemia 1998 12: (Suppl. 1) 33–36

    Google Scholar 

  32. Sievers EL, Larson RA, Estey E, Stadtmauoer EA, Berger MA, Eten C, Bernstein I, Appelbaum F . Interim analysis of the efficacy and safety of CMA-676 in patients at first relapse Blood 1998 92: (Suppl. 1) 2527a

    Google Scholar 

  33. Foa R . Interleukin-2 in acute leukemia Br J Haematol 1996 92: 1–8

    Article  CAS  Google Scholar 

  34. Hellstrand K, Mellqvist U, Wallhut E, Carneskog J, Kimby E, Celsing F, Brune M . Histamine and interleukin-2 in acute myelogenous leukemia Leuk Lymphoma 1997 27: 429–439

    Article  CAS  Google Scholar 

  35. Maraskovsky E, Brasel K, Teepe M, Roux ER, Oyman SD, Shortman K, McKenna HJ . Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 Ligand-treated mice. Multiple dendritic cell subpopulations identified J Exp Med 1996 184: 1953–1962

    Article  CAS  Google Scholar 

  36. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC . Flt3 ligand induces tumor regression and anti-tumor immune responses in vivo Nature Med 1997 3: 625–633

    Article  CAS  Google Scholar 

  37. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR . Flt3 ligand administration inhibits tumor growth in murine melanoma and lymphoma Cancer Res 1998 58: 380–383

    CAS  PubMed  Google Scholar 

  38. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Webke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K . Antitumor activity and immunotherapeutic properties of flt-3-ligand in a murine breast cancer model Cancer Res 1997 67: 3511–3516

    Google Scholar 

  39. Maraskovsky E, Roux E, Teepe M . Flt3 ligand increases peripheral blood dendritic cells in healthy volunteers Blood 1997 90: (Suppl. 6) 2585a

    Google Scholar 

  40. Arceci R . Clinical significance of P-glycoprotein in multidrug resistance malignancies Blood 1993 81: 2215–2222

    CAS  PubMed  Google Scholar 

  41. Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM . Mitoxantrone, etoposide and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study Cancer 1999 85: 358–367

    Article  CAS  Google Scholar 

  42. Advani R, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic B, Greenberg PL . Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar) Blood 1999 93: 787–795

    CAS  PubMed  Google Scholar 

  43. List AF, Kopeky KJ, Willman CL, Spier C, Dorr R, Flanerty L, Hynes H, Appelbaum F . Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high risk AML: a Southwest Oncology Group (SWOG) study Blood 1998 92: (Suppl. 1) 1281a

    Google Scholar 

  44. Büchner T, Hiddemann W, Koenigsmann M, Zuhlsdorf M, Wormann B, Boeckmann A, Freire EA, Innig G, Maschmeyer G, Ludwig WD . Recombinant human granulocyte–macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse Blood 1992 78: 1190–1197

    Google Scholar 

  45. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H . A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group New Engl J Med 1995 332: 1678–1683

    Article  CAS  Google Scholar 

  46. Link H, Wandt H, Schönrock-Nabulsi P, Ehninger G, Franke A, Gäckle R, Geer T, Strobel G, Linkesch W, Krieger O . G-CSF (lenograstim) after chemotherapy for acute myeloid leukemia; a placebo controlled trial Blood 1996 8: (Suppl. 1) 2654a

    Google Scholar 

  47. Goldstone AH, Burnett AK, Milligan EW . Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: an MRC study of 800 patients Blood 1997 90: (Suppl. 1) 3595a

    Google Scholar 

  48. Ohno R, Tomonaga M, Kobayashi T . Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia New Engl J Med 1990 323: 871–877

    Article  CAS  Google Scholar 

  49. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y . A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group Blood 1994 83: 2086–2092

    CAS  PubMed  Google Scholar 

  50. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S . Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor J Clin Oncol 1994 12: 671–678

    Article  CAS  Google Scholar 

  51. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group Blood 1997 90: 4710–4718

    CAS  PubMed  Google Scholar 

  52. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR . A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031) Blood 1998 91: 3605–3615

    Google Scholar 

  53. Stone RM, Burg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA . Granulocyte–macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B New Engl J Med 1995 325: 1671–1677

    Article  Google Scholar 

  54. Löwenberg B, Suciu S, Archimbaud E, Ossenkippele G, Verhoef GE, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R . Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgium Hemato-Oncology Cooperative Group Blood 1997 90: 2952–2961

    PubMed  Google Scholar 

  55. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R . Granulocyte–macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia. A randomized trial by the European Organization for Research in Treatment of Cancer and Leukemia Cooperative Groups J Clin Oncol 1996 14: 2150–2159

    Article  CAS  Google Scholar 

  56. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY, Lioure B, Witz B, Francois S, Desablens B . A placebo-controlled study of recombinant human granulocyte–macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) Blood 1998 91: 2722–2730

    CAS  PubMed  Google Scholar 

  57. Rowe JM, Liesveld JL . Commentary Review. Hematopoietic growth factors in acute leukemia Leukemia 1997 11: 328–341

    Article  CAS  Google Scholar 

  58. Rowe JM . Treatment of acute myeloid leukemia with cytokines. Effect on duration of neutropenia and response to infections Clin Infect Dis 1998 26: 1290–1294

    Article  CAS  Google Scholar 

  59. Bennett CL, Golub R, Waters T, Tallman M, Rowe JM . Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997 15: 227–235

    Article  CAS  Google Scholar 

  60. Bennett CL, Waters TM . Economic analyses in clinical trials or cooperative groups: operational consideration Cancer Invest 1997 15: 448–453

    Article  CAS  Google Scholar 

  61. Bassan R, Lerede T, Di Bona E, Rossi G, Togliani E, Rambaldi I, Buelli M, Viero P, Rodeghiero F, Izzi T, Corneo G, Barbui T . Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukemia: effects, role of patient pretreatment characteristics, and cost Leuk Lymphoma 1997 26: 153–161

    Article  CAS  Google Scholar 

  62. Desch CE, Over H . Neutropenia and neuoplasia and overview of the pharmacoeconomics of sargramostim in cancer therapy Clin Ther 1997 19: 847–865

    Article  CAS  Google Scholar 

  63. Bennett CL, Stinson TJ, Tallman MS, Stadtmauer EA, Marsh RW, Friedenberg W, Lazarus HM, Kaminer L, Golub RM, Rowe JM . Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: an Eastern Cooperative Oncology Group (E1490) trial Ann Oncol 1999 10: 177–182

    Article  CAS  Google Scholar 

  64. Uyl de Groot CA, Lowenberg B, Vellenga E, Suciu S, Willlenze R, Rutten FF . Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia Br J Haematol 1998 100: 629–636

    Article  CAS  Google Scholar 

  65. Scott RB . Hope for patients with acute leukemia Lancet 1957 1: 1053–1054

    Article  Google Scholar 

  66. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Hayes FA, Makary A, Tallman MS, Wiernik PH . A phase III study of priming and yeast-derived granulocyte–macrophage colony-stimulating-factor (rhuGM-CSF) for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group Blood 1998 22: (Suppl. 1) 2799a

    Google Scholar 

  67. Peterson B, George K, Bhalla K . A phase III trial with or without GM-CSF administered before and during high-dose cytarabine in patients with relapsed or refractory acute myelogenous leukemia (CALGB 9021) Proc Am Soc Clin Oncol 1996 15: (Suppl.) 3

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

    JM Rowe

  2. University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

    JM Rowe

Authors
  1. JM Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rowe, J. Treatment of acute myelogenous leukemia in older adults. Leukemia 14, 480–487 (2000). https://doi.org/10.1038/sj.leu.2401539

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401539

Keywords

This article is cited by

Search

Advanced search

Quick links